Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEconneCTD-ILD: Belimumab SC in CTD-Associated Interstitial Lung Disease
jRCT2011240027Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in connective tissue disease-associated interstitial lung disease (CTD-ILD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 6 more comparing Belimumab SC with Placebo SC (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity (FVC) in milliliters at Week 52. Started Oct 2024; status: recruiting.
02
Drugs
belimumab
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Autoimmune Myopathiespolymyositis (PM)
Beyond the preview
Go deeper on jRCT2011240027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240027.